Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

By K. Miller, L. Chap, F. Holmes, M. Cobleigh, P. Marcom, L. Fehrenbacher, M. Dickler, B. Overmoyer, J. Reimann, A. Sing and 2 more. Journal of Clinical Oncology, 2005

1,332 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/eaa618e81e977a57718e2d515f3ac3eecded59f6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. R. Kerbel
2. N. Ferrara
3. N. Vasudev
4. Andrew R Reynolds
5. Rakesh K. Jain
6. A. Adamis
7. H. Gerber
8. M. Shibuya

In Oncology

1. Andrew K. Joe
2. N. Ferrara
3. R. Kerbel
4. M. Jorge Cardoso
5. I. Weinstein
6. Larry Norton
7. Ian Krop
8. N. Vasudev

Citations in the corpus

• Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “The addition of bevacizumab to chemotherapy increases OS and/or response rates and PFS in colorectal cancer, non–small-cell lung cancer, and breast cancer.(18-21) When CALGB 80303 was initiated, it was plausible that these results would be replicated in pancreatic cancer.”
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. (2011, methodology): “All rights reserved. first-line phase III trials in MBC have shown the effectiveness of taxane (Tax) plus BV combinations in the initial treatment of human epidermal growth factor receptor 2 (HER2) –negative MBC.”
• Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. (2005, background): “The initial study with capecitabine did not show increased time to progression despite an increased remission rate [63].”
• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, result): “Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
• Angiogenesis as a therapeutic target (2005, background): “An early phase III trial of advanced, heavily pretreated, metastatic breast cancer showed that adding bevacizumab to capecitabine chemotherapy did not improve progression-free survival, despite a doubling of the response rate (that is, tumour shrinkage of 50p or more) in the bevacizumab-treated arm ”
• Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy (2006, background): “and that bevacizumab, a monoclonal antibody to VEGF, might have significant antitumor activity in carcinomas of the breast, colon and kidney”
• Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Metastatic 1st line Paclitaxel ± bevacizumab E2100 [40] Improvement in PFS not OS Docetaxel ± bevacizumab (HER-2 negative population) AVADO [41] Improvement in PFS, OS NA Capecitabine, taxane or anthracycline ± bevacizumab (HER-2 negative population) RIBBON-1 [42] Improvement in PFS but not in OS Do”
• Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, neutral): “Grade 3 HTN occurred in 1% to 18% of patients (18,19,107,108).”